Cardiovascular

AstraZeneca, Lilly, Novo Nordisk and Amgen all moved up in the rankings on the Scrip 100 leaderboard powered by impressive double-digit growth.

In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

Amgen has worked its way through biosimilar and generic competitors for key drugs, with Prolia and Xgeva now challenged, and may have a mega-blockbuster on its hands in obesity.

Aspire Biopharma has its eye on key strategic goals in 2025 and 2026, including for its lead candidate, a sublingual high-dose aspirin product that it hopes to position as a first-line emergency treatment for suspected heart attacks.

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

In this episode of the In Vivo podcast, Sweden-based Cereno Scientific's CEO discusses how his company is turning to an old drug to help patients with rare cardiovascular and pulmonary diseases.

North America will enjoy further generic competition to Entresto, after Sandoz became the first company to launch a generic version of Novartis’ heart failure blockbuster in Canada.

The drugmaker announced positive results from a 12,000-patient Phase III study showing Repatha is effective in patients who have not experienced a CV event.

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.

The European Medicines Agency is this week expected to recommend whether EU marketing approval should be granted to myriad new products, including therapies for bronchiectasis, RSV, menopause-related symptoms and type 2 diabetes.

Cessatech and Proveca’s investigational, sufentanil/ketamine fixed-dose combination analgesic nasal spray is among the latest drugs that the European Medicines Agency has started to review for potential pan-EU marketing authorization.